Stockscreener 앱 받기
16.23
2.99%
-0.50
시간 외 거래:
16.25
0.02
+0.12%
전일 마감가:
$16.73
열려 있는:
$16.68
하루 거래량:
256.59K
Relative Volume:
0.59
시가총액:
$5.79B
수익:
$5.21B
순이익/손실:
$-211.00M
주가수익비율:
-26.27
EPS:
-0.6179
순현금흐름:
$861.30K
1주 성능:
-5.42%
1개월 성능:
+6.36%
6개월 성능:
-5.69%
1년 성능:
+14.30%
1일 변동 폭
$15.98
$16.77
1주일 범위
$15.98
$17.46
52주 변동 폭
$13.09
$18.91
Bausch Lomb Corp Stock (BLCO) Company Profile
명칭
Bausch Lomb Corp
전화
908-541-5456
주소
520 APPLEWOOD CRESCENT, VAUGHAN
Compare BLCO vs ISRG, BDX, MDLN, ALC, RMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BLCO
Bausch Lomb Corp
|
16.23 | 5.79B | 5.21B | -211.00M | 861.30K | -0.6179 |
ISRG
Intuitive Surgical Inc
|
406.78 | 144.07B | 10.58B | 3.00B | 2.83B | 8.2437 |
BDX
Becton Dickinson Co
|
151.94 | 41.87B | 21.37B | 1.41B | 3.07B | 3.9437 |
MDLN
Medline Inc
|
41.04 | 34.70B | 29.14B | 1.07B | 1.05B | 1.1956 |
ALC
Alcon Inc
|
67.81 | 33.07B | 10.63B | 819.00M | 1.59B | 1.6577 |
RMD
Resmed Inc
|
203.87 | 29.57B | 5.54B | 1.52B | 1.74B | 10.37 |
Bausch Lomb Corp Stock (BLCO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-05 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2025-12-11 | 업그레이드 | Citigroup | Neutral → Buy |
| 2025-12-02 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2025-10-01 | 개시 | Goldman | Neutral |
| 2025-05-02 | 재확인 | H.C. Wainwright | Buy |
| 2025-03-28 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2024-12-11 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2024-12-02 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2024-10-15 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2024-07-10 | 개시 | Raymond James | Outperform |
| 2024-05-06 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2024-01-04 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2023-12-12 | 개시 | Stifel | Hold |
| 2023-10-03 | 재개 | Evercore ISI | Outperform |
| 2023-05-30 | 재개 | Morgan Stanley | Equal-Weight |
| 2023-03-09 | 개시 | Needham | Hold |
| 2022-12-21 | 개시 | Barclays | Equal Weight |
| 2022-09-12 | 개시 | H.C. Wainwright | Buy |
| 2022-07-26 | 개시 | RBC Capital Mkts | Outperform |
| 2022-06-24 | 개시 | Evercore ISI | Outperform |
| 2022-06-06 | 개시 | Citigroup | Buy |
| 2022-05-31 | 개시 | Deutsche Bank | Hold |
| 2022-05-31 | 개시 | Goldman | Neutral |
| 2022-05-31 | 개시 | Guggenheim | Buy |
| 2022-05-31 | 개시 | JP Morgan | Neutral |
| 2022-05-31 | 개시 | Jefferies | Buy |
| 2022-05-31 | 개시 | Morgan Stanley | Equal-Weight |
| 2022-05-31 | 개시 | Wells Fargo | Overweight |
| 2022-05-11 | 개시 | Cowen | Outperform |
모두보기
Bausch Lomb Corp 주식(BLCO)의 최신 뉴스
(BLCO) Technical Pivots with Risk Controls (BLCO:CA) - Stock Traders Daily
BLCO Stock Drops After-Hours — Bausch + Lomb Halts Glaucoma Eye Drop Program After Trial Failure - Stocktwits
Bausch + Lomb abandons glaucoma drops after phase 2 failure - MSN
Bausch + Lomb ditches BL1107 in glaucoma after trial miss - The Pharma Letter
Why Bausch + Lomb (BLCO) Stock Is Trading Lower Today - Yahoo Finance
Bausch + Lomb Ends Glaucoma Drug Development, Shifts Focus - Benzinga
Price to earnings forward of Bausch + Lomb Corporation – NYSE:BLCO - TradingView
Price to sales forward of Bausch + Lomb Corporation – NYSE:BLCO - TradingView
Bausch + Lomb Announces Phase 2 Results for Glaucoma Neuroprotective Candidate - BioSpace
Bausch + Lomb (BLCO) Could Be 57% Below Fair Value After Product Updates - Yahoo Finance
Bausch + Lomb Introduces Orphia, an AI-Powered Digital Health Platform - VisionMonday.com
Bausch + Lomb halts glaucoma eye drop program after trial miss - Investing.com UK
Bausch + Lomb halts glaucoma eye drop program after trial miss By Investing.com - Investing.com South Africa
Bausch + Lomb Ends Glaucoma Eye-Drop Development After Missed Trial Endpoint - Moomoo
Bausch to stop glaucoma eye drop development after trial miss - Reuters
BLCO stock stays supported by diversified eye-health portfolio - ad-hoc-news.de
Bausch + Lomb Corporation - Baystreet.ca
Stocks in play: Bausch + Lomb Corporation - The Globe and Mail
Bausch + Lomb introduces Orphia, an AI-powered digital health platform - Chain Drug Review
Bausch + Lomb launches AI-powered digital health platform - Investing.com
Bausch + Lomb launches AI-powered digital health platform By Investing.com - Investing.com Canada
Bausch + Lomb Introduces Orphia™, an AI-Powered Digital Health Platform Built to Return Physicians to Patient Care - marketscreener.com
Citi Maintains Bausch + Lomb Corp.(BLCO.US) With Buy Rating, Maintains Target Price $21 - Moomoo
Bausch + Lomb Will Release Second-Quarter 2026 Financial Results on July 29 - BioSpace
Bausch + Lomb Corp updates keep long-term strategy in focus - ad-hoc-news.de
Press Release: Bausch + Lomb Will Release Second-Quarter 2026 Financial Results on July 29 - Moomoo
Bausch + Lomb launches Bi-Blade+ vitrectomy cutter in Europe - Investing.com
(BLCO) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Bausch + Lomb Survey Finds That Addressing Dry Eye Symptoms Boosts Confidence, Lowers Anxiety - VisionMonday.com
BLCOBausch + Lomb Corp Volatility & Greeks - Finviz
Bausch + Lomb Corp (BLCO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
BLCO News | BAUSCH + LOMB CORP (NYSE:BLCO) - ChartMill
Bausch + Lomb survey finds dry eye symptoms linked to emotional health impacts - Optometry Times
BLCO Forecast — Price Target — Prediction for 2027 - TradingView
Bausch + Lomb survey finds dry eye affects emotional health By Investing.com - Investing.com Canada
Dry eye treatment tied to lower anxiety, better confidence in Bausch + Lomb survey - Stock Titan
Bausch + Lomb Corp updates investors on strategic focus, shares trade on NYSE - ad-hoc-news.de
INFUSE silicone hydrogel daily contact lenses from Bausch + Lomb Corp.a moisture-first take on al - ad-hoc-news.de
S2L Forecast — Price Target — Prediction for 2027 - TradingView
Bausch + Lomb Corporation Actuals & Estimates (NYSE:BLCO) - TradingView
Bausch + Lomb Corporation Actuals & Estimates (TSX:BLCO) - TradingView
Bausch + Lomb Tumbles as Technical and Governance Fears Mount - TipRanks
(BLCO) Risk Channels and Responsive Allocation - Stock Traders Daily
INFUSE Multifocal from Bausch + Lomb Corp.daily disposable lens for presbyopia - AD HOC NEWS
Cooper Cos. gains after report activist Jana takes stake - MSN
Bausch + Lomb (BLCO) Consolidates Near Support Following Minimal Daily ChangeFloat Adjusted Cap - dars.gov.et
Bausch + Lomb Corp (BLCO) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Bausch + Lomb Corp (BLCO) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Bausch + Lomb Corp (BLCO) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Bausch + Lomb Corp (BLCO) Institutional Confidence - TradingKey
Bausch + Lomb Corp (BLCO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Bausch Lomb Corp (BLCO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.71%
0.45%
자본화:
|
볼륨(24시간):